Having found that Lgr6 can regulate PO‐induced cardiac hypertrophy and metabolic reprogramming through the USP4/PPARα signaling pathway, we explored whether activation of Lgr6 using Maresin1, a selective agonist of Lgr6, could play a protective role in cardiac hypertrophy and offer clinical therapeutic potential (Figure8A). This evidence concerns the gene PPARA and cardiac hypertrophy.